Showing 2681-2690 of 5621 results for "".
- NIH Launches First U.S. Clinical Trial of Patient-Derived Stem Cell Therapy to Replace Dying Cells in Retinahttps://modernod.com/news/nih-launches-first-u-s-clinical-trial-of-patient-derived-stem-cell-therapy-to-replace-dying-cells-in-retina/2477175/Researchers at the National Eye Institute (NEI) are launching a clinical trial to test the safety of a novel patient-specific stem cell-based therapy to treat geographic atrophy, the advanced dry form of age-related macular degeneration (AMD). Geographic atrophy currently has no treatment.
- Eyesight Philanthropist James Chen Awarded Honorary Degree by University of Bathhttps://modernod.com/news/eyesight-philanthropist-james-chen-awarded-honorary-degree-by-university-of-bath/2477169/James Chen, a philanthropist committed to solving global problems associated with vision and eye care, has been awarded an honorary degree from the University of Bath, UK. He received his honorary LLD (Doctor of Laws) degree at the Assembly Rooms, Bath, on Tuesday 10 December (12:15 pm). I
- Limelight Bio Emerges with $75 Million to Develop Next Generation Gene Therapieshttps://modernod.com/news/limelight-bio-emerges-with-75-million-to-develop-next-generation-gene-therapies/2477141/Limelight Bio, a privately held, multi-platform, multi-disease biopharmaceutical company developing novel gene therapies, raised $75 million in new financing funded by Apple Tree Partners (ATP), a life sciences innovation fund. Founded in 2017, Limelight Bio has developed proprietary technologies
- RightEye Vision System Receives Breakthrough Device Designation from the FDA for Parkinson’s Disease Testhttps://modernod.com/news/righteye-vision-system-receives-breakthrough-device-designation-from-the-fda-for-parkinsons-disease-test/2477133/RightEye announced that the RightEye Vision System has received breakthrough device designation from the FDA for a Parkinson’s Disease Test. The designation is designed to streamline the market clearance
- ProQR Receives Orphan Drug Designation from FDA for QR-1123 for Autosomal Dominant Retinitis Pigmentosahttps://modernod.com/news/proqr-receives-orphan-drug-designation-from-fda-for-qr-1123-for-autosomal-dominant-retinitis-pigmentosa/2477112/ProQR Therapeutics announced that it received orphan drug designation (ODD) from the FDA for QR-1123, a first-in-class investigational antisense oligonucleotide designed to address the underlying cause of vision loss associated with autosomal dominant retinitis pigmentosa (adRP) due to the P23H m
- Lightmed Introduces New Design of LIGHTLas TruScan Pro Photocoagulatorhttps://modernod.com/news/lightmed-introduces-new-design-of-lightlas-truscan-pro-photocoagulator/2477108/Lightmed announced the launch of LIGHTLas TruScan Pro V2.0, the advanced and flexible pattern-scanning laser that’s configurable with up to four different wavelengths. The upgraded LIGHTLas TruScan Pro V2.0 features a slit lamp and integrated delivery system design, and a new ergonomic single col
- Tarsius Pharma Announces Granting of Orphan Drug Designation for TRS by the European Medicines Agencyhttps://modernod.com/news/tarsius-pharma-announces-granting-of-orphan-drug-designation-for-trs-by-the-european-medicines-agency/2477104/Tarsius Pharma announced that the European Medicines Agency (EMA) approved the designation of orphan drug for its TRS for treatment of noninfectious uveitis and has acknowledged the clinically relevant advantage for TRS in noninfectious uveitis patients with glaucoma not eligible for corticostero
- Nidek Launches the YC-200 and YC-200 S Plus in the United Stateshttps://modernod.com/news/nidek-launches-the-yc-200-and-yc-200-s-plus-in-the-united-states/2477101/Nidek has announced that the FDA has issued 510(k) clearance for the YC-200 Ophthalmic YAG Laser System. The YC-200 includes the S plus model for Selective Laser Trabeculoplasty (SLT). With FDA clearance, the YC-200 and YC-200 S plus are now commercially available in the United States. The
- EyePoint Pharmaceuticals Appoints George O. Elston as Chief Financial Officer and Head of Corporate Developmenthttps://modernod.com/news/eyepoint-pharmaceuticals-appoints-george-o-elston-as-chief-financial-officer-and-head-of-corporate-development/2477091/EyePoint Pharmaceuticals announced the appointment of George O. Elston as Chief Financial Officer and Head of Corporate Development. Mr. Elston has previously been a consultant to the company and will now transition into this permanent role effective immediately. In this role, Mr. Elston will lea
- Biogen Gains Commercialization Rights to Anti-VEGF Biosimilar Candidates After Deal with Samsung Bioepishttps://modernod.com/news/samsung-bioepis-enters-into-commercialization-agreement-for-next-generation-biosimilar-candidates/2477072/Samsung Bioepis has entered into a new commercialization agreement with Biogen for two biosimilar candidates under development by Samsung Bioepis, SB11 (ranibizumab) and SB15 (aflibercept), in the United States, Canada, Europe, Japan, and Australia. SB11, a biosimilar candidate referencing Lucent